SEC Form 4 · accession 0001827584-26-000013
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seshadri Neervannan
Officer — Chief Operating Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 9, 2026 · 4:12 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 4, 2026 | S | 4,564 | $85.00 | D | 78,532 | D | |
| Common StockF3 | holding | — | — | — | 475 | I | By daughter |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2Includes 305 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
- F3This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.